Skip to main content Skip to navigation
RY586 Mouse Anti-Human Ig, κ light chain
Product Details
Down Arrow Up Arrow


BD OptiBuild™
IGKC
Human (Tested in Development)
Mouse BALB/c X C57BL/6 IgG1, κ
Human
Flow cytometry (Qualified)
0.2 mg/ml
3514,931
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

Product Notices

  1. Researchers should determine the optimal concentration of this reagent for their individual applications.
  2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  3. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. CF™ is a trademark of Biotium, Inc.
  7. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
  8. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  9. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  10. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
753301 Rev. 1
Antibody Details
Down Arrow Up Arrow
TB28-2

The Anti-Kappa antibody, clone TB28-2, is derived from the hybridization of P3-X63-AG8.653 mouse myeloma cells with spleen cells isolated from CB6F1/J (C57BL/6J × BALB/cJ) mice immunized with human IgG, κ myeloma protein.The Anti-Kappa antibody specifically recognizes kappa (κ) light chains of human immunoglobulins.

753301 Rev. 1
Format Details
Down Arrow Up Arrow
RY586
The BD Horizon RealYellow™ 586 (RY586) Dye is part of the BD family of yellow-green dyes. It is a small organic fluorochrome with an excitation maximum (Ex Max) at 565-nm and an emission maximum (Em Max) at 586-nm. Driven by BD innovation, RY586 can be used on both spectral and conventional cytometers and is designed to be excited by the Yellow-Green laser (561-nm) with minimal excitation by the 488-nm Blue laser. For conventional instruments equipped with a Yellow-Green laser (561-nm), RY586 can be used as an alternative to PE and we recommend using an optical filter centered near 586-nm (eg, a 586/15-nm bandpass filter). For spectral instruments equipped with a Yellow-Green laser (561-nm), it can be used in conjunction with PE. Compared to PE, RY586 is similar in brightness, minimal spillover into Blue detectors, and increased spillover into the 610/20-nm (PE-CF594) detector. Please ensure that your instrument configuration (lasers and optical filters) is appropriate for this dye.
altImg
RY586
Yellow-Green 561 nm
564 nm
586 nm
753301 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "753301" on CiteAb

Development References (13)

  1. Ault KA. Flow cytometric evaluation of normal and neoplastic B cells. In: Rose NR, Friedman H, Fahey JL. Rose NR, Friedman H, Fahey JL, ed. Manual of Clinical Laboratory Immunology. 3rd ed.. Washington, DC: American Society for Microbiology; 1986:247-253. View Reference
  2. Foon KA, Todd RF. Immunologic classification of leukemia and lymphoma.. Blood. 1986; 68(1):1-31. (Methodology). View Reference
  3. Harris NL, Data RE. The distribution of neoplastic and normal B-lymphoid cells in nodular lymphomas: use of an immunoperoxidase technique on frozen sections.. Hum Pathol. 1982; 13(7):610-7. (Methodology: Immunohistochemistry). View Reference
  4. Kubagawa H, Gathings WE, Levitt D, Kearney JF, Cooper MD. Immunoglobulin isotype expression of normal pre-B cells as determined by immunofluorescence.. J Clin Immunol. 1982; 2(4):264-9. (Methodology: Immunofluorescence). View Reference
  5. Meis JM, Osborne BM, Butler JJ. A comparative marker study of large cell lymphoma, Hodgkin's disease, and true histiocytic lymphoma in paraffin-embedded tissue.. Am J Clin Pathol. 1986; 86(5):591-9. (Methodology). View Reference
  6. Picker LJ, Weiss LM, Medeiros LJ, Wood GS, Warnke RA. Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma.. Am J Pathol. 1987; 128(1):181-201. (Clone-specific: Immunohistochemistry). View Reference
  7. Smith BR, Weinberg DS, Robert NJ, et al. Circulating monoclonal B lymphocytes in non-Hodgkin's lymphoma.. N Engl J Med. 1984; 311(23):1476-81. (Methodology: Flow cytometry). View Reference
  8. Stetler-Stevenson M, Braylan RC. Flow cytometric analysis of lymphomas and lymphoproliferative disorders.. Semin Hematol. 2001; 38(2):111-23. (Methodology: Flow cytometry). View Reference
  9. Stites DP, Casavant CH, McHugh TM, et al. Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence.. Clin Immunol Immunopathol. 1986; 38(2):161-77. (Methodology: Flow cytometry). View Reference
  10. Tubbs RR, Sheibani K, Weiss RA, Sebek BA, Deodhar SD. Tissue immunomicroscopic evaluation of monoclonality of B-cell lymphomas: comparison with cell suspension studies.. Am J Clin Pathol. 1981; 76(1):24-8. (Methodology: Immunohistochemistry). View Reference
  11. Têtu B, Manning JT, Ordóñez NG. Comparison of monoclonal and polyclonal antibodies directed against immunoglobulin light and heavy chains in non-Hodgkin's lymphoma.. Am J Clin Pathol. 1986; 85(1):25-31. (Methodology: Immunohistochemistry). View Reference
  12. Weinberg DS, Pinkus GS, Ault KA. Cytofluorometric detection of B cell clonal excess: a new approach to the diagnosis of B cell lymphoma.. Blood. 1984; 63(5):1080-7. (Methodology: Flow cytometry). View Reference
  13. van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012; 26(9):1908-1975. (Methodology: Flow cytometry). View Reference
View All (13) View Less
753301 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Refer to manufacturer's instructions for use and related User Manuals and Technical Data Sheets before using this product as described.

Comparisons, where applicable, are made against older BD technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.